Health Condition 1: null- Stable Vitiligo
Conditions
Interventions
Intervention1: Non cultured Melanocyte transplant: Patients shall serve as their controls to optimize matching cases with controls. In that, two equal and where applicable, symmetric areas of stable v
Sponsors
Intitutional research committee
Eligibility
Inclusion criteria
Inclusion criteria: Patients with stable Vitilgo with no increase in size of lesion for past 06 months
Exclusion criteria
Exclusion criteria: 1) Unstable vitiligo (New lesion or extension of pre-existing lesion) 2) Vitiligo stabilized on systemic medical therapy 3) Evidence or history of keloid/hypertrophic scars. 4) Patients with chronic auto immune and infectious diseases e.g. DM, Thyroid disease, HTN, Hep B,C,HIV etc. 5) Patients with bleeding disorders or on medications affecting platelet function e.g. Ecosprin.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary measure of efficacy of treatment is the percentage of repigmentation 06(Six) months after surgery which will be assessed by two independent investigators and the lesser value will be used for assessment of results. Pigmentation will be graded as excellent(90%), very good (76â??90%), goo (51â??75%), fair (26â??50%), and poor (25%).Timepoint: One, three and six months | — |
Secondary
| Measure | Time frame |
|---|---|
| Improvement in Dermatology Life Quality Index (DLQI) score (assessed before and 6 months after surgery) and patient satisfaction assessed by asking patients to complete a patient satisfaction questionnaire. Additionally, adverse events will be noted as a safety outcome measure. Timepoint: Before and 6 months after surgery | — |
Countries
India
Contacts
Public ContactLt Col Vikas Pathania
Command Hospital Pune
Outcome results
None listed